Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
The management of patients with chronic myeloid leukemia (CML) has been revolutionized by the introduction of tyrosine kinase inhibitors (TKIs), which induce deep molecular responses so that treatment can eventually be discontinued, leading to treatment-free remission (TFR) in a subset of patients....
Main Authors: | Henrike Jacobi, Margherita Vieri, Marlena Bütow, Carolina Y. Namasu, Laura Flüter, Ivan G. Costa, Tiago Maié, Katharina Lindemann-Docter, Nicolas Chatain, Fabian Beier, Michael Huber, Wolfgang Wagner, Martina Crysandt, Tim H. Brümmendorf, Mirle Schemionek |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1212392/full |
Similar Items
-
P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS
by: Henrike Jacobi, et al.
Published: (2023-08-01) -
Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
by: Margherita Vieri, et al.
Published: (2023-06-01) -
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
by: Saskia Maletzke, et al.
Published: (2022-01-01) -
The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
by: Stefan Tillmann, et al.
Published: (2021-08-01) -
Epigenetic Clocks Are Not Accelerated in COVID-19 Patients
by: Julia Franzen, et al.
Published: (2021-08-01)